Characteristics of recurrence after completing adjuvant tamoxifen therapy for 5 years

被引：0
|
作者：
Lee, Eunshin [1 ]
Lee, Han-Byoel [1 ]
Kang, Young Joon [1 ]
Kim, Yun-Gyoung [1 ]
Yoo, Tae-kyung [1 ]
Kim, Jongjin [1 ]
Kim, Min Kyoon [1 ]
Moon, Hyeong-Gon [1 ]
Noh, Dong-Young [1 ]
Han, Wonshik [1 ]
机构：
[1] Seoul Natl Univ, Coll Med, Seoul 151, South Korea
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.SABCS14-P1-12-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-12-07
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Characteristics of recurrence after completing adjuvant tamoxifen therapy for 5 years: Retrospectove analysis.
    Lee, Eunshin
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Residual risk of breast cancer recurrence 5 years after adjuvant therapy
    Brewster, Abenaa M.
    Hortobagyi, Gabriel N.
    Broglio, Kristine R.
    Kau, Shu-Wan
    Santa-Maria, Cesar A.
    Arun, Banu
    Buzdar, Arnan U.
    Booser, Daniel J.
    Valero, Vincente
    Bondy, Melissa
    Esteva, Francisco J.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (16): : 1179 - 1183
  • [3] Adjuvant Therapy with Tamoxifen Better 10 than 5 Years?
    Bangemann, N.
    ONKOLOGE, 2013, 19 (04): : 316 - 318
  • [4] Retrospective evaluation of the Adjuvant! for breast cancer after 5 years of adjuvant tamoxifen (AAT) and other factors for prediction of recurrences (OFPR) following 5 years of adjuvant tamoxifen (AT)
    Barzi, A.
    Rybicki, L. A.
    Sisk, B. A.
    Yu, C.
    Kattan, M. W.
    Budd, G. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Adjuvant exemestane therapy after 5 years of tamoxifen: Rationale for the NSABP B-33 trial
    Mamounas, EP
    ONCOLOGY-NEW YORK, 2001, 15 (05): : 35 - 39
  • [6] Exemestane therapy after 2 to 3 years of tamoxifen therapy improved survival compared with 5 years of tamoxifen therapy alone
    Coombes, RC
    Hall, E
    Gibson, LJ
    ANNALS OF INTERNAL MEDICINE, 2005, 143 (11) : 824 - 824
  • [7] Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy:: Results from a randomized trial
    Nordenskjöld, B
    Rosell, J
    Rutqvist, LE
    Malmström, PO
    Bergh, J
    Bengtsson, NO
    Hatschek, T
    Wallgren, A
    Carstensen, J
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (21) : 1609 - 1610
  • [8] Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer
    Stewart, HJ
    Forrest, AP
    Everington, D
    McDonald, CC
    Dewar, JA
    Hawkins, RA
    Prescott, RJ
    George, WD
    BRITISH JOURNAL OF CANCER, 1996, 74 (02) : 297 - 299
  • [9] Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer
    Delea, Thomas E.
    Karnon, Jonathan
    Smith, Robert E.
    Johnston, Stephen R. D.
    Brandman, Jane
    Sung, Jennifer C. Y.
    Goss, Paul E.
    AMERICAN JOURNAL OF MANAGED CARE, 2006, 12 (07): : 374 - 386
  • [10] Exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): results of NSABP B-33
    Geyer, C. E.
    Mamounas, E.
    Jeong, J. -H.
    Wickerham, L.
    Ganz, P.
    Hutchins, L.
    Eisen, A.
    Ingle, J.
    Costantino, J.
    Wolmark, N.
    BREAST, 2007, 16 : S46 - S46
12345